가축용 치료제 및 백신 시장 기회, 성장 촉진요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Livestock Therapeutics & Vaccines Market was valued at USD 18.2 billion in 2025 and is estimated to grow at a CAGR of 5.6% to reach USD 31.5 billion by 2035.

Growth in the livestock therapeutics & vaccines market is driven by the increasing occurrence of infectious illnesses, parasitic conditions, and production-related health challenges affecting livestock populations worldwide. Rising demand for effective disease prevention and treatment solutions has encouraged continuous innovation across veterinary pharmaceuticals and animal health technologies. Advancements in biologics, vaccine development, veterinary therapeutics, diagnostic capabilities, precision animal healthcare, and modern livestock management systems are improving disease prevention, treatment efficiency, and overall herd health. At the same time, improvements in formulation technologies and preventive healthcare approaches are helping livestock producers enhance treatment compliance while reducing operational challenges. Greater adoption of digital animal health management, precision farming practices, and advanced breeding programs is strengthening disease surveillance and supporting more proactive livestock healthcare strategies. Continued investments in innovative veterinary medicines, preventive healthcare products, and next-generation biologics are expected to sustain market expansion throughout the forecast period. In addition, increasing commercial livestock production, higher spending on veterinary healthcare, expanding animal disease control initiatives, and growing awareness of responsible antimicrobial use continue to reinforce long-term growth across the global livestock therapeutics & vaccines market.

The therapeutics segment generated USD 11.1 billion in 2025. Strong demand for veterinary treatment products continues to support segment growth as livestock producers increasingly focus on maintaining herd health, improving productivity, reducing mortality, and minimizing economic losses. The expanding adoption of veterinary pharmaceuticals across commercial livestock production systems continues to strengthen the market position of the therapeutics segment throughout the forecast period.

The bacterial diseases segment was valued at USD 4.7 billion in 2025. Increasing disease prevalence across livestock populations continues to support demand for veterinary medicines, preventive vaccines, and diagnostic solutions designed to improve animal health outcomes. At the same time, greater emphasis on responsible antimicrobial use is encouraging the development of safer, more targeted treatment options while strengthening disease management practices across the livestock industry.

North America Livestock Therapeutics & Vaccines Market accounted for 40% share in 2025 and is anticipated to grow at a CAGR of 5.3% through 2035. Regional growth is supported by a well-established animal healthcare ecosystem, extensive commercial livestock production, and favorable regulatory initiatives focused on disease prevention and animal health management. Continued investment in veterinary research, innovative biologics, advanced vaccines, and therapeutic products is expected to further strengthen market expansion across the region.

Major companies operating in the global livestock therapeutics & vaccines market include Zoetis, Merck Animal Health (MSD Animal Health), Boehringer Ingelheim Animal Health, Elanco Animal Health, Ceva Sante Animale, Virbac, HIPRA, Vetoquinol, Phibro Animal Health, Indian Immunologicals, Vaxxinova, Biogenesis Bago, Bioveta, Neogen Corporation, and Norbrook. Companies operating in the livestock therapeutics & vaccines market are strengthening their market position by expanding research and development activities, enhancing biologics and vaccine portfolios, and introducing advanced veterinary therapeutics that improve disease prevention and treatment outcomes. Many manufacturers are increasing investments in innovative production technologies, expanding manufacturing capacity, and improving product quality to address growing global demand. Strategic collaborations, acquisitions, licensing agreements, and distribution partnerships continue to support geographic expansion and broaden customer reach.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product type trends
  • 2.2.3 Animal type trends
  • 2.2.4 Disease indication trends
  • 2.2.5 Route of administration trends
  • 2.2.6 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of infectious and transboundary animal diseases
    • 3.2.1.2 Growing global demand for meat, milk, eggs, and other animal-derived products
    • 3.2.1.3 Increasing adoption of preventive vaccination and herd health management programs
    • 3.2.1.4 Expansion of commercial livestock farming and intensive animal production systems
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Regulatory restrictions on antimicrobial use in food animals
    • 3.2.2.2 Stringent regulatory approval processes for veterinary products
  • 3.2.3 Market opportunities
    • 3.2.3.1 Increasing investment in aquaculture therapeutics and fish vaccines
    • 3.2.3.2 Rising adoption of long-acting injectable therapeutics and next-generation biologics
• 3.3 Growth potential analysis
• 3.4 Technology landscape
  • 3.4.1 Current technology
  • 3.4.2 Emerging technologies
• 3.5 Pricing trend analysis (Driven by Primary Research)
  • 3.5.1 Historical pricing trends
  • 3.5.2 Pricing trend analysis, by product type
• 3.6 Regulatory landscape (Driven by primary research)
  • 3.6.1 North America
  • 3.6.2 Europe
  • 3.6.3 Asia Pacific
  • 3.6.4 Latin America
  • 3.6.5 Middle East and Africa
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Product pipeline analysis (Driven by Primary Research)
• 3.10 Impact of AI and generative AI on the market
• 3.11 Future market trends (Driven by primary research)

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Therapeutics
  • 5.2.1 Antibiotics/anti-infectives
  • 5.2.2 Antiparasitics agents
  • 5.2.3 Anti-inflammatory agents
  • 5.2.4 Corticosteroids
  • 5.2.5 Tranquilizers
  • 5.2.6 Cardiovascular drugs
  • 5.2.7 Gastrointestinal drugs
  • 5.2.8 Other therapeutics
• 5.3 Vaccines
  • 5.3.1 Live attenuated vaccines
  • 5.3.2 Inactivated vaccines
  • 5.3.3 Recombinant & subunit vaccines
  • 5.3.4 Toxoid vaccines
  • 5.3.5 Other vaccines

Chapter 6 Market Estimates and Forecast, By Animal Type, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Poultry
• 6.3 Cattle
• 6.4 Swine
• 6.5 Sheep and goats
• 6.6 Aquaculture
• 6.7 Other animal types

Chapter 7 Market Estimates and Forecast, By Disease Indication, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Bacterial diseases
• 7.3 Viral diseases
• 7.4 Parasitic diseases
• 7.5 Fungal diseases
• 7.6 Other disease indications

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Injectable (parenteral)
• 8.3 Oral
• 8.4 Topical
• 8.5 Intranasal/inhalation
• 8.6 Other route of administration

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 Veterinary hospital pharmacies
• 9.3 E-commerce
• 9.4 Retail pharmacies
• 9.5 Other distribution channels

Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Zoetis
• 11.2 Merck Animal Health (MSD Animal Health)
• 11.3 Boehringer Ingelheim Animal Health
• 11.4 Elanco Animal Health
• 11.5 Ceva Sante Animale
• 11.6 Virbac
• 11.7 HIPRA
• 11.8 Vetoquinol
• 11.9 Phibro Animal Health
• 11.10 Indian Immunologicals
• 11.11 Vaxxinova
• 11.12 Biogenesis Bago
• 11.13 Bioveta
• 11.14 Neogen Corporation
• 11.15 Norbrook